Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Sullivan

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Cellular Oncology (Dordrecht, Netherlands)|October 4, 2011
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myelomaFeng Chen, Alexandra Pisklakova, Ming Li, et al.
Seminars in Cancer Biology|March 18, 2014
Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agentsJoel G Turner, Jana Dawson, Christopher L Cubitt, et al.
Cancer Biology & Therapy|March 3, 2016
Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironmentAlexandra Pisklakova, Eileen Grigson, Maria Ozerova, et al.
Journal of Cell Science|June 3, 2004
Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signalsJoel G Turner, Roxanne Engel, Jennifer A Derderian, et al.
Plos One|January 31, 2015
Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent mannerEileen R Grigson, Maria Ozerova, Alexandra Pisklakova, et al.
Blood|November 28, 2007
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapyYulia Nefedova, Daniel M Sullivan, Sophia C Bolick, et al.
Personalized Medicine|May 18, 2018
The creation of an integrated health-information platform: building the framework to support personalized medicineRobert M Wenham, Daniel M Sullivan, Mark Hulse, et al.
Molecular Cancer Therapeutics|December 24, 2005
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlatesDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Cancer Research|May 4, 2005
Valproic acid alters chromatin structure by regulation of chromatin modulation proteinsDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Experimental Cell Research|April 20, 2004
The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cellsRoxane Engel, Nikola I Valkov, Jana L Gump, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Cellular Oncology (Dordrecht, Netherlands)|October 4, 2011
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myelomaFeng Chen, Alexandra Pisklakova, Ming Li, et al.
Seminars in Cancer Biology|March 18, 2014
Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agentsJoel G Turner, Jana Dawson, Christopher L Cubitt, et al.
Cancer Biology & Therapy|March 3, 2016
Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironmentAlexandra Pisklakova, Eileen Grigson, Maria Ozerova, et al.
Journal of Cell Science|June 3, 2004
Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signalsJoel G Turner, Roxanne Engel, Jennifer A Derderian, et al.
Plos One|January 31, 2015
Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent mannerEileen R Grigson, Maria Ozerova, Alexandra Pisklakova, et al.
Blood|November 28, 2007
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapyYulia Nefedova, Daniel M Sullivan, Sophia C Bolick, et al.
Personalized Medicine|May 18, 2018
The creation of an integrated health-information platform: building the framework to support personalized medicineRobert M Wenham, Daniel M Sullivan, Mark Hulse, et al.
Molecular Cancer Therapeutics|December 24, 2005
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlatesDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Cancer Research|May 4, 2005
Valproic acid alters chromatin structure by regulation of chromatin modulation proteinsDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Experimental Cell Research|April 20, 2004
The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cellsRoxane Engel, Nikola I Valkov, Jana L Gump, et al.
Pageof 9